BioMerieux Stock-Based Compensation 2017-2024 | BMXMF

BioMerieux stock-based compensation for the twelve months ending December 31, 2024 was $0M, a 0% increase year-over-year.

  • BioMerieux annual stock-based compensation for 2024 was $0.025B, a 18.76% increase from 2023.
  • BioMerieux annual stock-based compensation for 2023 was $0.021B, a 55.66% increase from 2022.
  • BioMerieux annual stock-based compensation for 2022 was $0.014B, a 6.63% decline from 2021.

BioMerieux Stock-Based Compensation 2017-2024 | BMXMF

  • BioMerieux annual stock-based compensation for 2024 was $0.025B, a 18.76% increase from 2023.
  • BioMerieux annual stock-based compensation for 2023 was $0.021B, a 55.66% increase from 2022.
  • BioMerieux annual stock-based compensation for 2022 was $0.014B, a 6.63% decline from 2021.
Related Stocks
Company NameMarket
Cap
Danaher (DHR)$139.4B
CVS Health (CVS)$80.1B
Elevance Health (ELV)$68.3B
Cencora (COR)$57.1B
DiDi Global (DIDIY)$27.2B
Labcorp Holdings (LH)$20.7B
Natera (NTRA)$19.6B
EUROFINS SCIENT (ERFSF)$13.9B
CochLear (CHEOY)$13.1B
Solventum (SOLV)$12.8B
ICON (ICLR)$11.9B
Revvity (RVTY)$11.3B
Viatris (VTRS)$10.9B
Medpace Holdings (MEDP)$9.2B
Avantor (AVTR)$9.1B
Sonic Healthcare (SKHHY)$8.8B
HealthEquity (HQY)$8.7B
Caris Life Sciences,�Inc (CAI)$8B
Charles River Laboratories (CRL)$7.7B
Amplifon S.p.A (AMFPF)$5.4B
Bausch + Lomb (BLCO)$5B
BrightSpring Health Services (BTSG)$3.5B
Sotera Health (SHC)$3.2B
Surgery Partners (SGRY)$2.9B
Alignment Healthcare (ALHC)$2.6B
Concentras Parent (CON)$2.5B
Organon (OGN)$2.5B
GeneDx Holdings (WGS)$2.3B
Progyny (PGNY)$2B
PACS (PACS)$1.9B